660
Participants
Start Date
June 23, 2013
Primary Completion Date
November 30, 2025
Study Completion Date
January 31, 2028
Craniospinal Irradiation with boost to the primary tumor site
All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
Cyclophosphamide
Route of Administration (ROA): Intravenously (IV)
Cisplatin
ROA: IV
Vincristine
ROA: IV
Vismodegib
ROA: Orally (PO)
Pemetrexed
ROA: IV
Gemcitabine
ROA: IV
Aerobic Training
Neurocognitive Remediation
Starship Children's Hospital, Auckland
Sydney Children's Hospital, Randwick
Children's Hospital at Westmead, Westmead
Royal Children's Hospital, Melbourne, Melbourne
Queensland Children's Hospital, Brisbane
Perth Children's Hospital, Perth
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Duke Children's Hospital and Health Center, Durham
Medical University of South Carolina, Charleston
University of Florida, Gainesville
Arnold Palmer Hospital for Children, Orlando
St. Jude Children's Research Hospital, Memphis
Children's Hospital and Clinics of Minnesota, Minneapolis
University of Texas Southwestern Medical Center, Dallas
Cook Children's Medical Center, Fort Worth
Rady Children's Hospital, San Diego
Lucille Packard Children's Hospital at Stanford University Medical Center, Palo Alto
Yale University, New Haven
Texas Children's Cancer Center, Houston
Alberta Children's Hospital, Calgary
The Hospital for Sick Children, Toronto
Centre Hospitalier Universitaire Sainte-Justine, Montreal
Collaborators (1)
Genentech, Inc.
INDUSTRY
National Cancer Institute (NCI)
NIH
St. Jude Children's Research Hospital
OTHER